The data indicated that mutations in BRAF are prevalent in 50% of melanoma patient samples, followed by NRAS (30%) and NF1 (14%) and 15% of melanomas did not harbor somatic mutations in BRAF, NRAS or NF1 (20). Here, NRAS is linked to melanoma.